Nicholas Wilson | Vice President, Immunology & Stromal Biology TME TRC
Bristol-Myers Squibb

Nicholas Wilson, Vice President, Immunology & Stromal Biology TME TRC, Bristol-Myers Squibb

Nicholas Wilson Ph.D is a Vice President at Bristol Myers Squibb. Nick leads the Immunology & Stromal Biology group at Bristol Myers Squibb’s Tumor Microenvironment Thematic Research Center (TME TRC) located in Redwood City, California. Nick has over 15 years of industry experience in oncology research and early development, spanning a range of therapeutic modalities. Prior to joining Bristol Myers Squibb in 2020, Nick spent time at biotechnology companies in the Bay Area, Boston, and Australia, including Gilead, Novartis, Agenus  Merck KGA and CSL Limited. Nick obtained his Ph.D in Medical Biology at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia studying dendritic cell antigen presentation. He completed his postdoctoral research training at Genentech studying Fcg receptor biology. Nick holds several patents on immunotherapeutic molecules currently in clinical development, and has authored/co-authored a number of primary and review publications in the field of immunology and immuno-oncology.


WVIC/WAC Day 1 - Nov 29 @ 13:50

Panel: Understanding the TME; what’s left to learn?

  • How can we apply proteomics to the TME – how is this informing multiple targets?
  • Balancing power of profiling and proteomics – will proteomics ever be ready for plug and play in the clinic?
  • Advances in imaging the TME
  • Characterizing effective T cell responses in and that track to the TME
  • Non-tumor components of the TME as a therapeutic strategy -stromal cells, myeloid cells, other tissue resident cells

WVIC/WAC Day 1 - Nov 29 @ 17:20

Studies informing mechanisms of resistance in oncology

WVIC/WAC Day 2 - Nov 30 @ 10:00

Challenges & opportunities in moving immuno-oncology drugs into earlier lines of therapy

  • What are the challenges that need to be overcome before we can move immunotherapies into earlier stages?
  • What is effect of moving earlier in moving into adjuvant/neoadjuvant space? The need to understand progression much earlier in disease.
  • What are our current assumptions – what data do we need to pressure test them? How do we collect data? What data do we need?
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall